Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 1
1952 1
1953 4
1954 2
1955 1
1962 1
1963 1
1964 1
1965 4
1966 3
1967 3
1968 2
1969 2
1970 1
1971 7
1972 3
1973 8
1974 5
1975 5
1976 5
1977 6
1978 5
1979 8
1980 5
1981 2
1982 4
1983 6
1984 7
1985 14
1986 14
1987 15
1988 11
1989 12
1990 14
1991 19
1992 23
1993 26
1994 20
1995 21
1996 20
1997 16
1998 14
1999 11
2000 23
2001 23
2002 30
2003 25
2004 31
2005 27
2006 29
2007 29
2008 32
2009 34
2010 41
2011 34
2012 51
2013 33
2014 54
2015 48
2016 64
2017 65
2018 100
2019 101
2020 92
2021 132
2022 103
2023 44

Text availability

Article attribute

Article type

Publication date

Search Results

1,435 results

Results by year

Filters applied: . Clear all
Page 1
New drugs for multiple sclerosis: new treatment algorithms.
Cree BAC, Hartung HP, Barnett M. Cree BAC, et al. Among authors: barnett m. Curr Opin Neurol. 2022 Jun 1;35(3):262-270. doi: 10.1097/WCO.0000000000001063. Curr Opin Neurol. 2022. PMID: 35674067 Review.
Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2.
Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Graf J, et al. Among authors: barnett m. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):e919. doi: 10.1212/NXI.0000000000000919. Print 2021 Jan. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 33411674 Free PMC article. Review.
Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, Hartung HP. Graf J, et al. Among authors: barnett m. Neurol Neuroimmunol Neuroinflamm. 2020 Dec 16;8(1):e918. doi: 10.1212/NXI.0000000000000918. Print 2021 Jan. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 33406479 Free PMC article. Review.
Scleral schism.
van der Worp E, Johns L, Barnett M. van der Worp E, et al. Among authors: barnett m. Cont Lens Anterior Eye. 2019 Feb;42(1):1-2. doi: 10.1016/j.clae.2018.11.004. Epub 2018 Dec 1. Cont Lens Anterior Eye. 2019. PMID: 30514612 No abstract available.
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.
Rio-Machin A, Vulliamy T, Hug N, Walne A, Tawana K, Cardoso S, Ellison A, Pontikos N, Wang J, Tummala H, Al Seraihi AFH, Alnajar J, Bewicke-Copley F, Armes H, Barnett M, Bloor A, Bödör C, Bowen D, Fenaux P, Green A, Hallahan A, Hjorth-Hansen H, Hossain U, Killick S, Lawson S, Layton M, Male AM, Marsh J, Mehta P, Mous R, Nomdedéu JF, Owen C, Pavlu J, Payne EM, Protheroe RE, Preudhomme C, Pujol-Moix N, Renneville A, Russell N, Saggar A, Sciuccati G, Taussig D, Toze CL, Uyttebroeck A, Vandenberghe P, Schlegelberger B, Ripperger T, Steinemann D, Wu J, Mason J, Page P, Akiki S, Reay K, Cavenagh JD, Plagnol V, Caceres JF, Fitzgibbon J, Dokal I. Rio-Machin A, et al. Among authors: barnett m. Nat Commun. 2020 Feb 25;11(1):1044. doi: 10.1038/s41467-020-14829-5. Nat Commun. 2020. PMID: 32098966 Free PMC article.
Introduction.
Barnett ML, Ly DP, Marcotte L. Barnett ML, et al. Healthc (Amst). 2016 Jun;4(2):79. doi: 10.1016/j.hjdsi.2016.06.001. Healthc (Amst). 2016. PMID: 27343153 No abstract available.
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.
McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X, Li Y, Byun J, Dunning A, Pooley KA, Qian DC, Ji X, Liu G, Timofeeva MN, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman CA, Wilkens LR, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden HFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty JA, Barnett MP, Chen C, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Wichmann HE, Manz J, Muley TR, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd FA, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston RS, McLaughlin J, Stevens VL, Joubert P, Lamontagne M, Nickle DC, Obei… See abstract for full author list ➔ McKay JD, et al. Among authors: barnett mp. Nat Genet. 2017 Jul;49(7):1126-1132. doi: 10.1038/ng.3892. Epub 2017 Jun 12. Nat Genet. 2017. PMID: 28604730 Free PMC article.
Response.
Downer K, Gustin J, Lincoln T, Goodman L, Barnett MD. Downer K, et al. Among authors: barnett md. Chest. 2022 Jun;161(6):e398. doi: 10.1016/j.chest.2022.02.017. Chest. 2022. PMID: 35680331 No abstract available.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S, Skibina O, Kuhle J, Hodgkinson S, Boz C, Alroughani R, Lechner-Scott J, Barnett M, Izquierdo G, Prat A, Horakova D, Kubala Havrdova E, Macdonell R, Patti F, Khoury SJ, Slee M, Karabudak R, Onofrj M, Van Pesch V, Prevost J, Monif M, Jokubaitis V, van der Walt A, Butzkueven H; MSBase Study Group. Zhu C, et al. Among authors: barnett m. J Neurol Neurosurg Psychiatry. 2022 Dec;93(12):1330-1337. doi: 10.1136/jnnp-2022-330104. Epub 2022 Oct 19. J Neurol Neurosurg Psychiatry. 2022. PMID: 36261289
Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis.
Yeh WZ, Widyastuti PA, Van der Walt A, Stankovich J, Havrdova E, Horakova D, Vodehnalova K, Ozakbas S, Eichau S, Duquette P, Kalincik T, Patti F, Boz C, Terzi M, Yamout BI, Lechner-Scott J, Sola P, Skibina OG, Barnett M, Onofrj M, Sá MJ, McCombe PA, Grammond P, Ampapa R, Grand'Maison F, Bergamaschi R, Spitaleri DLA, Van Pesch V, Cartechini E, Hodgkinson S, Soysal A, Saiz A, Gresle M, Uher T, Maimone D, Turkoglu R, Hupperts RM, Amato MP, Granella F, Oreja-Guevara C, Altintas A, Macdonell RA, Castillo-Trivino T, Butzkueven H, Alroughani R, Jokubaitis VG; MSBase Study Group. Yeh WZ, et al. Among authors: barnett m. Neurology. 2021 Apr 20;96(24):e2989-3002. doi: 10.1212/WNL.0000000000012084. Online ahead of print. Neurology. 2021. PMID: 33879599 Free PMC article.
1,435 results